Mark Plavsic Sells 7,383 Shares of Aura Biosciences, Inc. (NASDAQ:AURA) Stock

Aura Biosciences, Inc. (NASDAQ:AURA) CTO Mark Plavsic sold 7,383 shares of the firm’s stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $9.85, for a total value of $72,722.55. Following the completion of the sale, the chief technology officer now directly owns 121,132 shares in the company, valued at approximately $1,193,150.20. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Aura Biosciences Stock Performance

NASDAQ:AURA traded up $0.39 during mid-day trading on Wednesday, reaching $10.25. The stock had a trading volume of 211,556 shares, compared to its average volume of 169,225. The stock has a market capitalization of $507.82 million, a P/E ratio of -5.44 and a beta of 0.37. The firm has a 50 day moving average price of $8.52 and a two-hundred day moving average price of $8.00. Aura Biosciences, Inc. has a one year low of $5.99 and a one year high of $12.35.

Aura Biosciences (NASDAQ:AURA) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.04. Research analysts forecast that Aura Biosciences, Inc. will post -1.7 earnings per share for the current year.

Wall Street Analyst Weigh In

AURA has been the subject of several recent analyst reports. HC Wainwright restated a “buy” rating and issued a $21.00 price objective on shares of Aura Biosciences in a research report on Friday, September 13th. JMP Securities boosted their price target on shares of Aura Biosciences from $19.00 to $23.00 and gave the stock a “market outperform” rating in a research note on Friday, September 13th. Lifesci Capital raised shares of Aura Biosciences to a “strong-buy” rating in a report on Monday, September 9th. Finally, Evercore ISI raised shares of Aura Biosciences to a “strong-buy” rating in a report on Monday, September 16th. Three analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $21.67.

Institutional Trading of Aura Biosciences

Several hedge funds have recently added to or reduced their stakes in the business. SG Americas Securities LLC bought a new position in shares of Aura Biosciences during the third quarter valued at about $169,000. Long Focus Capital Management LLC grew its position in Aura Biosciences by 113.4% during the 2nd quarter. Long Focus Capital Management LLC now owns 1,057,188 shares of the company’s stock worth $7,992,000 after acquiring an additional 561,766 shares during the last quarter. The Manufacturers Life Insurance Company increased its stake in Aura Biosciences by 14.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 64,452 shares of the company’s stock worth $487,000 after purchasing an additional 8,194 shares during the period. Renaissance Technologies LLC increased its stake in Aura Biosciences by 26.3% in the 2nd quarter. Renaissance Technologies LLC now owns 72,100 shares of the company’s stock worth $545,000 after purchasing an additional 15,000 shares during the period. Finally, Dimensional Fund Advisors LP lifted its position in Aura Biosciences by 20.0% in the second quarter. Dimensional Fund Advisors LP now owns 250,375 shares of the company’s stock valued at $1,892,000 after purchasing an additional 41,711 shares during the last quarter. 96.75% of the stock is owned by institutional investors.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.